NCT00000526

Brief Summary

To determine whether drug treatment of asymptomatic ventricular arrhythmias in post-myocardial infarction patients reduced the incidence of sudden cardiac death and total mortality.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Aug 1986

Longer than P75 for phase_3 cardiovascular-diseases

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 1986

Completed
11.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 1998

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

October 27, 1999

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 28, 1999

Completed
Last Updated

May 6, 2016

Status Verified

August 1, 2004

First QC Date

October 27, 1999

Last Update Submit

May 5, 2016

Conditions

Cardiovascular DiseasesCoronary DiseaseDeath, Sudden, CardiacHeart ArrestHeart DiseasesMyocardial InfarctionMyocardial IschemiaVentricular Arrhythmia

Interventions

encainideDRUG
flecainideDRUG
moricizineDRUG

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Men and women with ventricular premature depolarization six days to two years after the start of myocardial infarction.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Related Publications (56)

  • Pratt CM, Moye LA. The cardiac arrhythmia suppression trial. Casting suppression in a different light. Circulation. 1995 Jan 1;91(1):245-7. doi: 10.1161/01.cir.91.1.245. No abstract available.

    PMID: 7805210BACKGROUND

  • el-Sherif N, Denes P, Katz R, Capone R, Mitchell LB, Carlson M, Reynolds-Haertle R. Definition of the best prediction criteria of the time domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period. The Cardiac Arrhythmia Suppression Trial/Signal-Averaged Electrocardiogram (CAST/SAECG) Substudy Investigators. J Am Coll Cardiol. 1995 Mar 15;25(4):908-14. doi: 10.1016/0735-1097(94)00504-j.

    PMID: 7884096BACKGROUND

  • Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989 Aug 10;321(6):406-12. doi: 10.1056/NEJM198908103210629.

    PMID: 2473403BACKGROUND

  • Bigger JT Jr. The events surrounding the removal of encainide and flecainide from the Cardiac Arrhythmia Suppression Trial (CAST) and why CAST is continuing with moricizine. J Am Coll Cardiol. 1990 Jan;15(1):243-5. doi: 10.1016/0735-1097(90)90209-8. No abstract available.

    PMID: 2104884BACKGROUND

  • Morganroth J, Bigger JT Jr, Anderson JL. Treatment of ventricular arrhythmias by United States cardiologists: a survey before the Cardiac Arrhythmia Suppression Trial results were available. Am J Cardiol. 1990 Jan 1;65(1):40-8. doi: 10.1016/0002-9149(90)90023-t.

    PMID: 1688481BACKGROUND

  • Pratt CM, Moye LA. The Cardiac Arrhythmia Suppression Trial: background, interim results and implications. Am J Cardiol. 1990 Jan 16;65(4):20B-29B. doi: 10.1016/0002-9149(90)91287-g.

    PMID: 2105049BACKGROUND

  • Pratt CM. The Cardiac Arrhythmia Suppression Trial. Introduction: The aftermath of the CAST--a reconsideration of traditional concepts. Am J Cardiol. 1990 Jan 16;65(4):1B-2B. doi: 10.1016/0002-9149(90)91283-c. No abstract available.

    PMID: 2404392BACKGROUND

  • Pratt CM, Brater DC, Harrell FE Jr, Kowey PR, Leier CV, Lowenthal DT, Messerli F, Packer M, Pritchett EL, Ruskin JN. Clinical and regulatory implications of the Cardiac Arrhythmia Suppression Trial. Am J Cardiol. 1990 Jan 1;65(1):103-5. doi: 10.1016/0002-9149(90)90034-x. No abstract available.

    PMID: 1688479BACKGROUND

  • Pratt CM, Moye L. The cardiac arrhythmia suppression trial: implications for antiarrhythmic drug development. J Clin Pharmacol. 1990 Nov;30(11):967-74. doi: 10.1002/j.1552-4604.1990.tb03580.x. No abstract available.

    PMID: 2122983BACKGROUND

  • Bigger JT Jr. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment. Am J Cardiol. 1990 Feb 20;65(8):3D-10D; discussion 68D-71D. doi: 10.1016/0002-9149(90)91410-8.

    PMID: 2106253BACKGROUND

  • Morganroth J, Bigger JT Jr. Pharmacologic management of ventricular arrhythmias after the cardiac arrhythmia suppression trial. Am J Cardiol. 1990 Jun 15;65(22):1497-503. doi: 10.1016/0002-9149(90)91362-a. No abstract available.

    PMID: 2091621BACKGROUND

  • Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21;324(12):781-8. doi: 10.1056/NEJM199103213241201.

    PMID: 1900101BACKGROUND

  • Epstein AE, Bigger JT Jr, Wyse DG, Romhilt DW, Reynolds-Haertle RA, Hallstrom AP. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled. J Am Coll Cardiol. 1991 Jul;18(1):14-9. doi: 10.1016/s0735-1097(10)80210-4.

    PMID: 1904891BACKGROUND

  • Wyse DG, Hallstrom A, McBride R, Cohen JD, Steinberg JS, Mahmarian J. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy. J Am Coll Cardiol. 1991 Jul;18(1):20-8. doi: 10.1016/s0735-1097(10)80211-6.

    PMID: 1904892BACKGROUND

  • Hallstrom AP, Verter J, Friedman L. Randomizing responders. Cardiac Arrhythmia Suppression Trial (CAST) investigators. Control Clin Trials. 1991 Aug;12(4):486-503. doi: 10.1016/0197-2456(91)90009-b.

    PMID: 1657526BACKGROUND

  • Denes P, Gillis AM, Pawitan Y, Kammerling JM, Wilhelmsen L, Salerno DM. Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol. 1991 Oct 1;68(9):887-96. doi: 10.1016/0002-9149(91)90404-9.

    PMID: 1718158BACKGROUND

  • Capone RJ, Pawitan Y, el-Sherif N, Geraci TS, Handshaw K, Morganroth J, Schlant RC, Waldo AL. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. J Am Coll Cardiol. 1991 Nov 15;18(6):1434-8. doi: 10.1016/0735-1097(91)90671-u.

    PMID: 1939943BACKGROUND

  • Hallstrom AP, Greene HL, Huther ML. The healthy responder phenomenon in non-randomized clinical trials. CAST Investigators. Stat Med. 1991 Oct;10(10):1621-31. doi: 10.1002/sim.4780101013.

    PMID: 1947517BACKGROUND

  • Greene HL, Roden DM, Katz RJ, Woosley RL, Salerno DM, Henthorn RW. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. J Am Coll Cardiol. 1992 Apr;19(5):894-8. doi: 10.1016/0735-1097(92)90267-q.

    PMID: 1552108BACKGROUND

  • Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992 Jul 23;327(4):227-33. doi: 10.1056/NEJM199207233270403.

    PMID: 1377359BACKGROUND

  • Akiyama T, Pawitan Y, Campbell WB, Papa L, Barker AH, Rubbert P, Friedman L, Keller M, Josephson RA. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators. J Am Geriatr Soc. 1992 Jul;40(7):666-72. doi: 10.1111/j.1532-5415.1992.tb01957.x.

    PMID: 1607582BACKGROUND

  • Shea S, Bigger JT Jr, Campion J, Fleiss JL, Rolnitzky LM, Schron E, Gorkin L, Handshaw K, Kinney MR, Branyon M. Enrollment in clinical trials: institutional factors affecting enrollment in the cardiac arrhythmia suppression trial (CAST). Control Clin Trials. 1992 Dec;13(6):466-86. doi: 10.1016/0197-2456(92)90204-d.

    PMID: 1334819BACKGROUND

  • Willund I, Gorkin L, Pawitan Y, Schron E, Schoenberger J, Jared LL, Shumaker S. Methods for assessing quality of life in the cardiac arrhythmia suppression trial (CAST). Qual Life Res. 1992 Jun;1(3):187-201. doi: 10.1007/BF00635618.

    PMID: 1301128BACKGROUND

  • Reynolds-Haertle RA, McBride R. Single vs. double data entry in CAST. Control Clin Trials. 1992 Dec;13(6):487-94. doi: 10.1016/0197-2456(92)90205-e.

    PMID: 1334820BACKGROUND

  • Gorkin L, Schron EB, Brooks MM, Wiklund I, Kellen J, Verter J, Schoenberger JA, Pawitan Y, Morris M, Shumaker S. Psychosocial predictors of mortality in the Cardiac Arrhythmia Suppression Trial-1 (CAST-1). Am J Cardiol. 1993 Feb 1;71(4):263-7. doi: 10.1016/0002-9149(93)90788-e.

    PMID: 8427165BACKGROUND

  • Peters RW, Zoble RG, Liebson PR, Pawitan Y, Brooks MM, Proschan M. Identification of a secondary peak in myocardial infarction onset 11 to 12 hours after awakening: the Cardiac Arrhythmia Suppression Trial (CAST) experience. J Am Coll Cardiol. 1993 Oct;22(4):998-1003. doi: 10.1016/0735-1097(93)90408-s.

    PMID: 8409074BACKGROUND

  • Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, Seals AA, Anderson JL, Cohen JD, Capone RJ, Wyse DG. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA. 1993 Nov 24;270(20):2451-5.

    PMID: 8230622BACKGROUND

  • Friedman LM, Bristow JD, Hallstrom A, Schron E, Proschan M, Verter J, DeMets D, Fisch C, Nies AS, Ruskin J, et al. Data monitoring in the cardiac arrhythmia suppression trial. Online J Curr Clin Trials. 1993 Jul 31;Doc No 79:[5870 words; 53 paragraphs]. doi: 10.1007/0-387-30107-0_18.

    PMID: 8306012BACKGROUND

  • Peters RW, Mitchell LB, Brooks MM, Echt DS, Barker AH, Capone R, Liebson PR, Greene HL. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). J Am Coll Cardiol. 1994 Feb;23(2):283-9. doi: 10.1016/0735-1097(94)90408-1.

    PMID: 8294678BACKGROUND

  • Wyse DG, Morganroth J, Ledingham R, Denes P, Hallstrom A, Mitchell LB, Epstein AE, Woosley RL, Capone R. New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the Cardiac Arrhythmia Suppression Trial and its pilot study. The CAST and CAPS Investigators. J Am Coll Cardiol. 1994 Apr;23(5):1130-40. doi: 10.1016/0735-1097(94)90601-7.

    PMID: 8144779BACKGROUND

  • Hochman JS, Brooks MM, Morris M, Ahmad T. Prognostic significance of left ventricular aneurysm in the Cardiac Arrhythmia Suppression Trial (CAST) population. Am Heart J. 1994 Apr;127(4 Pt 1):824-32. doi: 10.1016/0002-8703(94)90549-5.

    PMID: 8154420BACKGROUND

  • Denes P, el-Sherif N, Katz R, Capone R, Carlson M, Mitchell LB, Ledingham R. Prognostic significance of signal-averaged electrocardiogram after thrombolytic therapy and/or angioplasty during acute myocardial infarction (CAST substudy). Cardiac Arrhythmia Suppression Trial (CAST) SAECG Substudy Investigators. Am J Cardiol. 1994 Aug 1;74(3):216-20. doi: 10.1016/0002-9149(94)90359-x.

    PMID: 8037124BACKGROUND

  • Anderson JL, Platia EV, Hallstrom A, Henthorn RW, Buckingham TA, Carlson MD, Carson PE. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation. 1994 Dec;90(6):2843-52. doi: 10.1161/01.cir.90.6.2843.

    PMID: 7994829BACKGROUND

  • Brooks MM, Gorkin L, Schron EB, Wiklund I, Campion J, Ledingham RB. Moricizine and quality of life in the Cardiac Arrhythmia Suppression Trial II (CAST II). Control Clin Trials. 1994 Dec;15(6):437-49. doi: 10.1016/0197-2456(94)90002-7.

    PMID: 7851106BACKGROUND

  • Kennedy HL, Brooks MM, Barker AH, Bergstrand R, Huther ML, Beanlands DS, Bigger JT, Goldstein S. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol. 1994 Oct 1;74(7):674-80. doi: 10.1016/0002-9149(94)90308-5.

    PMID: 7942525BACKGROUND

  • Hallstrom A, Pratt CM, Greene HL, Huther M, Gottlieb S, DeMaria A, Young JB. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. J Am Coll Cardiol. 1995 May;25(6):1250-7. doi: 10.1016/0735-1097(94)00553-3.

    PMID: 7722117BACKGROUND

  • A symposium: the cardiac arrhythmia suppression trial--does it alter our concepts of and approaches to ventricular arrhythmias? Woodland, Texas, August 9, 1989. Am J Cardiol. 1990 Jan 16;65(4):1B-42B. No abstract available.

    PMID: 2404393BACKGROUND

  • Akiyama T, Pawitan Y, Greenberg H, Kuo CS, Reynolds-Haertle RA. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol. 1991 Dec 15;68(17):1551-5. doi: 10.1016/0002-9149(91)90308-8.

    PMID: 1720917BACKGROUND

  • Hallstrom AP, Anderson JL, Carlson M, Davies R, Greene HL, Kammerling JM, Romhilt DW, Duff HJ, Huther M. Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial. Am Heart J. 1995 Jul;130(1):71-9. doi: 10.1016/0002-8703(95)90238-4.

    PMID: 7611126BACKGROUND

  • Friedmann E, Thomas SA. Pet ownership, social support, and one-year survival after acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial (CAST). Am J Cardiol. 1995 Dec 15;76(17):1213-7. doi: 10.1016/s0002-9149(99)80343-9.

    PMID: 7502998BACKGROUND

  • Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. J Clin Psychiatry. 1994 Sep;55 Suppl A:83-7; discussion 88-9, 98-100.

    PMID: 7961547BACKGROUND

  • Josephson RA, Chahine RA, Morganroth J, Anderson J, Waldo A, Hallstrom A. Prediction of cardiac death in patients with a very low ejection fraction after myocardial infarction: a Cardiac Arrhythmia Suppression Trial (CAST) study. Am Heart J. 1995 Oct;130(4):685-91. doi: 10.1016/0002-8703(95)90064-0.

    PMID: 7572573BACKGROUND

  • Peters RW, Brooks MM, Todd L, Liebson PR, Wilhelmsen L. Smoking cessation and arrhythmic death: the CAST experience. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. J Am Coll Cardiol. 1995 Nov 1;26(5):1287-92. doi: 10.1016/0735-1097(95)00328-2.

    PMID: 7594045BACKGROUND

  • Kellen JC, Ettinger A, Todd L, Brezsnyak ML, Campion J, McBride R, Thomas S, Corum J, Schron E. The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice. Am J Crit Care. 1996 Jan;5(1):19-25.

    PMID: 8680488BACKGROUND

  • Schron EB, Brooks MM, Gorkin L, Kellen JC, Morris M, Campion J, Shumaker SA, Corum J. Relation of sociodemographic, clinical, and quality-of-life variables to adherence in the cardiac arrhythmia suppression trial. Cardiovasc Nurs. 1996 Mar-Apr;32(2):1-6.

    PMID: 8697488BACKGROUND

  • Peters RW, Brooks MM, Zoble RG, Liebson PR, Seals AA. Chronobiology of acute myocardial infarction: cardiac arrhythmia suppression trial (CAST) experience. Am J Cardiol. 1996 Dec 1;78(11):1198-201. doi: 10.1016/s0002-9149(96)00595-4.

    PMID: 8960574BACKGROUND

  • Goldstein S, Zoble RG, Akiyama T, Cohen JD, Lancaster S, Liebson PR, Rapaport E, Goldberg AD, Peters RW, Gillis AM. Relation of circadian ventricular ectopic activity to cardiac mortality. CAST Investigators. Am J Cardiol. 1996 Oct 15;78(8):881-5. doi: 10.1016/s0002-9149(96)00461-4.

    PMID: 8888659BACKGROUND

  • Obias-Manno D, Friedmann E, Brooks MM, Thomas SA, Haakenson C, Morris M, Wimbush F, Somelofski C, Goldner F. Adherence and arrhythmic mortality in the cardiac arrhythmia suppression trial (CAST). Ann Epidemiol. 1996 Mar;6(2):93-101. doi: 10.1016/1047-2797(95)00134-4.

    PMID: 8775589BACKGROUND

  • Gorkin L, Schron EB, Handshaw K, Shea S, Kinney MR, Branyon M, Campion J, Bigger JT Jr, Sylvia SC, Duggan J, Stylianou M, Lancaster S, Ahern DK, Follick MJ. Clinical trial enrollers vs. nonenrollers: the Cardiac Arrhythmia Suppression Trial (CAST) Recruitment and Enrollment Assessment in Clinical Trials (REACT) project. Control Clin Trials. 1996 Feb;17(1):46-59. doi: 10.1016/0197-2456(95)00089-5.

    PMID: 8721801BACKGROUND

  • Anderson JL, Karagounis LA, Stein KM, Moreno FL, Ledingham R, Hallstrom A. Predictive value for future arrhythmic events of fractal dimension, a measure of time clustering of ventricular premature complexes, after myocardial infarction. CAST Investigators. Cardia Arrhythmia Suppression Trial. J Am Coll Cardiol. 1997 Jul;30(1):226-32. doi: 10.1016/s0735-1097(97)00108-3.

    PMID: 9207646BACKGROUND

  • Thomas SA, Friedmann E, Wimbush F, Schron E. Psychological factors and survival in the cardiac arrhythmia suppression trial (CAST): a reexamination. Am J Crit Care. 1997 Mar;6(2):116-26.

    PMID: 9172848BACKGROUND

  • Shumaker SA, Brooks MM, Schron EB, Hale C, Kellen JC, Inkster M, Wimbush FB, Wiklund I, Morris M. Gender differences in health-related quality of life among postmyocardial infarction patients: brief report. CAST Investigators. Cardiac Arrhythmia Suppression Trials. Womens Health. 1997 Spring;3(1):53-60.

    PMID: 9106370BACKGROUND

  • Every NR, Hlatky MA, McDonald KM, Weaver WD, Hallstrom AP. Estimating the proportion of post-myocardial infarction patients who may benefit from prophylactic implantable defibrillator placement from analysis of the CAST registry. Cardiac Arrhythmia Suppression Trial. Am J Cardiol. 1998 Sep 1;82(5):683-5, A8. doi: 10.1016/s0002-9149(98)00417-2.

    PMID: 9732904BACKGROUND

  • Hallstrom A, Friedman L, Denes P, Rizo-Patron C, Morris M; CAST Investigators; AVID Investigators. Do arrhythmia patients improve survival by participating in randomized clinical trials? Observations from the Cardiac Arrhythmia Suppression Trial (CAST)and the Antiarrhythmics Versus Implantable Defibrillators Trial (AVID). Control Clin Trials. 2003 Jun;24(3):341-52. doi: 10.1016/s0197-2456(03)00002-3.

    PMID: 12757998BACKGROUND

  • Ruskin JN. The cardiac arrhythmia suppression trial (CAST). N Engl J Med. 1989 Aug 10;321(6):386-8. doi: 10.1056/NEJM198908103210608. No abstract available.

    PMID: 2501683BACKGROUND

  • Goldstein S, Brooks MM, Ledingham R, Kennedy HL, Epstein AE, Pawitan Y, Bigger JT. Association between ease of suppression of ventricular arrhythmia and survival. Circulation. 1995 Jan 1;91(1):79-83. doi: 10.1161/01.cir.91.1.79.

    PMID: 7805221BACKGROUND

MeSH Terms

Conditions

Cardiovascular DiseasesCoronary DiseaseDeath, Sudden, CardiacHeart ArrestHeart DiseasesMyocardial InfarctionMyocardial Ischemia

Interventions

EncainideFlecainideMoricizine

Condition Hierarchy (Ancestors)

Vascular DiseasesDeath, SuddenDeathPathologic ProcessesPathological Conditions, Signs and SymptomsInfarctionIschemiaNecrosis

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPhenothiazinesSulfur CompoundsMorpholinesOxazinesHeterocyclic Compounds, 3-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Alfred Hallstrom

    University of Washington

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
PREVENTION
Sponsor Type
NIH

Study Record Dates

First Submitted

October 27, 1999

First Posted

October 28, 1999

Study Start

August 1, 1986

Study Completion

March 1, 1998

Last Updated

May 6, 2016

Record last verified: 2004-08